2022年11月12日

Fintech新闻2022年11月12日,帕洛阿尔托,加州(业务线)- #生物技术Medable Inc .)、行业领先的技术平台,以病人为中心的临床试验,今天宣布任命一位领袖“分散的临床试验产品矩阵®评估2022年达到峰值“珠峰集团连续第二年。雷竞技推荐码怎么获得报告评估分散的临床试验(DCT)产品从24公司基于视觉、能力和市场的影响。Medable额定最高领导人象限得分最高的视野,能力和市场的影响。这个识别强调Medable行业转向dct的领导。自2020年以来,Medable部署软件即服务平台通过300多个分散和混合的临床试验在60个国家,为全球超过一百万人。雷竞技推荐码怎么获得通过最小化需要面对面的网站访问,Medable客户取得了前所未有的成果,包括入学快200%,成本降低50%。事实上,一项新的研究从塔夫茨中心药物开发研究表明,平均而言,dct可以实现净经济利益从5至13倍II期和III期试验,相当于大约1000万美元分别ROI和3900万美元的ROI。“我们不能骄傲被珠峰公认的领袖集团连续第二年,”米歇尔Longmire说Medable的首席执行官和创始人之一。“临床研究的未来将由病人首次定义方法进行试验,Medable准备为生命科学公司提供一个可伸缩的、企业SaaS平台获得他们需要的工具成功的在他们的整个投资组合。雷竞技推荐码怎么获得我们将继续引领着向试验更方便,有效,所有人群的代表,使有效的疗法达到患者更快。” Everest Group’s PEAK Matrix® Assessment is based on two dimensions and multiple criteria: Market impact: Measures impact in the market via market adoption (number of clients, revenue base, year-over-year growth), portfolio mix (diversity of client base) and value delivered to clients based on customer feedback and other measures. Vision and capability: Measures ability to deliver products successfully via five sub-dimensions, including vision and strategy; technology capability; flexibility and ease of deployment; engagement and commercial model; and support. Medable stands out from competitors based on the following strengths: End-to-end, unified, and modular solution combining technology and services; Highly rated product quality and user experience from patients, sites, and sponsors; Extensive partnership network that includes leaders in systems integration, technology, data, direct-to-patient concierge, remote sites, and retail pharmacies; Quick and responsive client feedback and support services; Scalable solutions, as evidenced by various enterprise-level deals, including GSK ; and Digital certifications ( Medable Academy ) empowering professionals to design and build DCT studies on the Medable platform, increasing DCT adoption at research sites. The company has also made major strides since last year’s assessment – a $304 million fundraising round , expansion into Europe, a milestone pharmacy collaboration with CVS Health , making CNBC’s inaugural list of Top 2022 Startups for the Enterprise, plus new product offerings for patient consent , and oncology and vaccine trials. “Our strategy at Medable is to lead the industry with a proven, evidence-based platform that focuses on improving the patient’s journey,” said MaryAnne Rizk, Ph.D, Chief Strategy Officer at Medable. “As life sciences organizations are moving toward enterprise DCT platform adoption, the ability to scale with flexibility through an ecosystem of partners is fundamental to deliver transformational outcomes.” About Medable Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. Medable connects patients, sites and clinical trial teams to improve patient access, experience and outcomes. Medable’s software has been named a Leader in the industry by both Everest Group and IDC. Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Contacts +1 (610) 420-3413